Warning! GuruFocus detected
1 Severe warning sign
with CTOR.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Citius Oncology Inc
NAICS : 325412
SIC : 2834
ISIN : US17331Y1091
Description
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.76 | |||||
| 9-Day RSI | 51.3 | |||||
| 14-Day RSI | 47.75 | |||||
| 3-1 Month Momentum % | -20 | |||||
| 6-1 Month Momentum % | -11.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.34 | |||||
| Quick Ratio | 0.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -59.01 | |||||
| ROA % | -32.02 | |||||
| ROIC % | -37.3 | |||||
| ROCE % | -52.51 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 1.64 | |||||
| PB Ratio | 1.09 | |||||
| Price-to-Operating-Cash-Flow | 353.5 | |||||
| EV-to-EBIT | -2.97 | |||||
| EV-to-Forward-EBIT | -2.25 | |||||
| EV-to-EBITDA | -2.97 | |||||
| EV-to-Forward-Revenue | 2.13 | |||||
| EV-to-FCF | -12.52 | |||||
| Earnings Yield (Greenblatt) % | -33.67 | |||||
| FCF Yield % | -9.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTOR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Citius Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.31 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 47.75 | ||
| 14-Day ATR ($) | 0.159686 | ||
| 20-Day SMA ($) | 0.746455 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.5506 - 4.42 | ||
| Shares Outstanding (Mil) | 71.55 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Citius Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Citius Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Citius Oncology Inc Frequently Asked Questions
What is Citius Oncology Inc(CTOR)'s stock price today?
The current price of CTOR is $0.71. The 52 week high of CTOR is $4.42 and 52 week low is $0.55.
When is next earnings date of Citius Oncology Inc(CTOR)?
The next earnings date of Citius Oncology Inc(CTOR) is 2025-08-08 Est..
Does Citius Oncology Inc(CTOR) pay dividends? If so, how much?
Citius Oncology Inc(CTOR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers